U.S. Markets close in 6 hrs 16 mins

Auxilium recieves cautious assessment for Xiaflex, says Leerink

Leerink said the IQWiG released its assessment for Auxilium's/Pfizer's (PFE) Xiaflex for Dupuytren's contracture and Esai's Halavan for breast cancer. The firm said both received a "no proven added benefit" assessment and views the decision as concerning for the drugs and believes it reduces visibility into German reimbursement.